埃默里与阿特罗波斯健康合作以优化药物方案-动脉网

Emory, Atropos Health partner to enhance medication protocols

MobiHealthNews 等信源发布 2025-02-27 20:02



可切换为仅中文







Photo: FatCamera/Getty Images

照片来源：FatCamera/Getty Images

Academic health system

学术健康系统

Emory Healthcare

埃默里医疗保健

is partnering with

正在与...合作

Atropos Health

阿特罗波斯健康

, a company that translates real-world clinical data into real-world evidence, to advance medication formulary decisions and protocols.

，这是一家将真实世界临床数据转化为真实世界证据的公司，以推动药物目录决策和协议的制定。

Emory is piloting a program that aims to advance patient care by allowing clinical questions to be answered in real-time using Atropos' platform.

埃默里正在试点一项计划，该计划旨在通过使用Atropos平台实时回答临床问题来提升患者护理水平。

The Atropos Evidence Network allows Emory users to run studies on national datasets and local Emory data. Clinicians can also use Atropos' Green Button to access real-world evidence, generating results through supervised evidence development or a fully automated generative AI version (ChatRWD).

阿特罗波斯证据网络（Atropos Evidence Network）允许埃默里大学的用户在全国性数据集和本地埃默里数据上运行研究。临床医生还可以使用阿特罗波斯的“绿色按钮”获取真实世界证据，通过受监督的证据开发或全自动的生成式人工智能版本（ChatRWD）生成结果。

ChatRWD is an LLM-powered chat tool for clinical research that aims to eliminate hallucination risk by employing the company's real-world data platform, GENEVA OS.

ChatRWD 是一款针对临床研究的大型语言模型驱动的聊天工具，旨在通过使用公司的实际数据平台 GENEVA OS 来消除幻觉风险。

'Atropos Health provides a means to answer questions not specifically or robustly answered in published data; Atropos surfaces practice-based evidence where evidence-based medicine does not exist,' Dr. Alistair Erskine, enterprise chief information and digital officer for Emory Healthcare and Emory University, said in a statement. .

“At罗波斯健康提供了一种方法，可以回答已发表数据中未具体或强有力回答的问题；在没有循证医学的地方，Atropos揭示了基于实践的证据，”埃默里医疗保健和埃默里大学的企业首席信息和数字官阿里斯泰尔·厄斯金博士在一份声明中表示。

'We are already seeing early success as one of our users explored real-world outcomes, adverse events and costs of a drug that will improve our drug therapy protocol and benefit Emory patients.'

“我们已经看到了初步的成功，因为我们的一位用户探索了一种药物的真实世界结果、不良事件和成本，这将改进我们的药物治疗方案，并使埃默里患者受益。”

THE LARGER TREND

更大的趋势

In January, Atropos

一月，阿特罗波斯

announced a partnership

宣布了一项合作伙伴关系

with

xCures

, an AI-powered healthcare data retrieval company, to harness RWE-based insights to support patient care. The collaboration would leverage AI, the Atropos Evidence Network and the xCures Platform to develop and deploy prognostic and decision-support tools for care providers.

，一家由人工智能驱动的医疗数据检索公司，利用基于真实世界证据（RWE）的洞察来支持患者护理。此次合作将利用人工智能、Atropos证据网络和xCures平台，开发并部署面向护理提供者的预后和决策支持工具。

It also

它也

partnered

合伙的

with pharma giant

与制药巨头

Merck

默克

to generate RWE, replicate studies and produce rapid insights and analytics on real-world data.

生成真实世界证据 (RWE)，复制研究并快速获得真实世界数据的洞察和分析。

Last year, Atropos secured

去年，阿特罗波斯确保了

$33 million in Series B funding

3300万美元的B轮融资

and announced that healthcare data analytics company

并宣布医疗保健数据分析公司

Arcadia

阿卡迪亚

joined its

加入了它的

health portfolio

健康档案

, giving Arcadia's provider customers and life sciences users access to Atropos' offerings.

，让阿卡迪亚的供应商客户和生命科学用户能够访问阿特罗波斯的产品。

Through the partnership, Arcadia joined Atropos' Evidence Network, allowing its users access to Atropos' portfolio of applications to support clinical decision-making in value-based care.

通过合作，Arcadia 加入了 Atropos 的证据网络，使其用户能够访问 Atropos 的应用程序组合，以支持基于价值的护理中的临床决策。

In 2023, Atropios

2023年，阿特罗皮奥斯

announced a partnership

宣布了一项合作伙伴关系

with data-sharing technology platform

搭载数据共享技术平台

Datavant

数据万特

, which would allow each company's members to access the other company's offerings.

，这将允许各公司的成员访问另一家公司的产品。

In 2022, Atropos secured